EXPORT CITATION

Chapter-076 Superiority of Telmisartan: ARB, the First Choice in Cardiodiabetes

BOOK TITLE: Cardiodiabetes Update: A Textbook of Cardiology

Author
1. Ganguly Kajal
2. De Santanu
3. Kar Auriom
4. Basu Biswadev
ISBN
9789352703043
DOI
10.5005/jp/books/14130_77
Edition
1/e
Publishing Year
2018
Pages
6
Author Affiliations
1. NRS Medical College, Kolkata, West Bengal, India, Nil Ratan Sircar Medical College and Hospital, Kolkata, West Bengal, India, Nil Ratan Sircar Medical College, Kolkata, West Bengal, India, AMRI Hospital, Saltlake, Kolkata, West Bengal, India
2. NRS Medical College, Kolkata, West Bengal, India, Nil Ratan Sircar Medical College, Kolkata, West Bengal, India
3. NRS Medical College, Kolkata, West Bengal, India, Nil Ratan Sircar Medical College and Hospital, Kolkata, West Bengal, India, Nil Ratan Sircar Medical College, Kolkata, West Bengal, India, Narayana Multispeciality Hospital, Barasat, West Bengal, India
4. NRS Medical College, Kolkata, West Bengal, India
Chapter keywords
Antihypertensive drug, blood pressure, cardiovascular event, myocardial infarction, MI, heart failure, HF, angiotensin II receptor blocker, ARB

Abstract

All antihypertensive drugs lower blood pressure (BP), and the main benefit based on a large number of randomized trials is due to lowering of BP per se and is largely independent of the drugs employed. The choice of antihypertensive agents in diabetic patients is based upon their ability to do the following: prevent mortality; prevent adverse cardiovascular events, such as myocardial infarction (MI), stroke, and heart failure; prevent the progression of renal disease, if present. This chapter also covers the ACE inhibitors versus ARB in diabetes and ALLHAT trial. The ALLHAT trial is by far the largest prospective study of the treatment of mild hypertension and assessed the efficacy of different medications.

Related Books

© 2019 Jaypee Brothers Medical Publishers (P) LTD.   |   All Rights Reserved